Despite the small sample size and the lack of in vivo post-TKI patient cells, this list suggests the existence of a transcriptomic signature in CML that is not affected by TKI and which is likely independent from the TK activity of BCR-ABL1 (although not necessarily BCR-ABL1 independent). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.